Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bapoma case report: BRCA1-associated protein-inactivated melanocytic tumor as first presenting symptom of BRCA1-associated protein tumor predisposition syndrome in a pediatric patient.

JAAD case reports·2026

Same author

Cutis laxa associated with a missense variant in elastin gene.

JAAD case reports·2025

Same author

Guideline-based Approach in the Management of Atopic Dermatitis.

Immunology and allergy clinics of North America·2025

Same author

Locally Advanced Cutaneous Squamous Cell Carcinoma Arising in the Setting of Bothnian Palmoplantar Keratoderma.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2025

Same author

Ruxolitinib cream for discoid lupus erythematosus: An open-label pilot study of 10 subjects.

Journal of the American Academy of Dermatology·2024

Same author

Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series.

Pediatric hematology and oncology·2024

Search research articles

Related Experiment Video

Updated: Jun 28, 2025

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Prostaglandin E-induced polycyclic cutaneous eruption with geometric features.

Ananya Shah¹, Jinia El-Feghaly¹, Alexandra M Bender¹

¹Department of Dermatology, University of Rochester, Rochester, New York, USA.

Pediatric Dermatology

|April 18, 2024

Summary

Prostaglandin E1 (PGE1) is crucial for infants with congenital heart disease (CHD). A case study shows a rash from PGE1 can resolve with reduced dosage, potentially allowing continued treatment.

Keywords:

cutaneous drug eruption neonate polycyclic

More Related Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Related Experiment Videos

Last Updated: Jun 28, 2025

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Area of Science:

Neonatal cardiology
Pediatric pharmacology
Dermatology

Background:

Prostaglandin E1 (PGE1) maintains patency of the ductus arteriosus.
PGE1 is vital for ductus-dependent congenital heart disease (CHD) management.
Infants with specific CHDs require PGE1 to ensure pulmonary blood flow or proper great artery positioning.

Observation:

A neonate receiving PGE1 for CHD developed a distinct rash.
The rash presented as bright erythematous annular and polycyclic patches.
The dermatological reaction appeared on day 2 of PGE1 administration.

Findings:

Reducing the PGE1 dosage led to spontaneous resolution of the rash.
The observed rash is a potential side effect of PGE1 treatment.
The case suggests PGE1 therapy may not always require interruption due to skin reactions.

Implications:

This finding could inform clinical management of PGE1 side effects.
It highlights the possibility of continuing essential PGE1 treatment with dosage adjustments.
Further investigation into PGE1-induced dermatological reactions in neonates is warranted.